Pub Date : 2021-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2021036437
Neeraj Taneja, Aftab Alam, Ranjana S Patnaik, Tannu Taneja, Sonia Gupta, Sunil M K
Oral cancer is the 11th most common cancer in the world with a high morbidity rate. Various conventional therapies have been used for the treatment of oral cancer such as surgery, radiotherapy, and chemotherapy used either alone or in combination but these have many limitations, making them unsuitable for treating oral cancer. Nanotechnology has been emerged out as an innovative tool in the field of oral cancer which has proved to provide effective results overcoming the limitations of conventional drug therapies. This system involves a nanoparticle drug delivery system based on a targeted therapy in which therapeutic drugs or agents act on the targeted cells without affecting normal healthy cells. Literature has shown that several nanoparticles, organic and inorganic nanoparticles, have been used as the drug delivery system in different types of oral cancers such as oral squamous cell carcinoma, cancer of the tongue, head, and neck cancers. Drugs like cisplatin, 5-fluorouracil, methotrexate, doxorubicin, etc., when coated with nano-polymers have shown better results compared with conventional drugs in oral cancer. Other nanoparticles such as liposomes, hydrogels, nanodiamonds, carbon rods, etc. have also been used with minimal side effects. This paper aims to review and discuss various nanotechnology systems in the field of oral cancer and to evaluate the efficacy of these systems in treating oral cancer compared with conventional drug delivery methods.
{"title":"Understanding Nanotechnology in the Treatment of Oral Cancer: A Comprehensive Review.","authors":"Neeraj Taneja, Aftab Alam, Ranjana S Patnaik, Tannu Taneja, Sonia Gupta, Sunil M K","doi":"10.1615/CritRevTherDrugCarrierSyst.2021036437","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2021036437","url":null,"abstract":"<p><p>Oral cancer is the 11th most common cancer in the world with a high morbidity rate. Various conventional therapies have been used for the treatment of oral cancer such as surgery, radiotherapy, and chemotherapy used either alone or in combination but these have many limitations, making them unsuitable for treating oral cancer. Nanotechnology has been emerged out as an innovative tool in the field of oral cancer which has proved to provide effective results overcoming the limitations of conventional drug therapies. This system involves a nanoparticle drug delivery system based on a targeted therapy in which therapeutic drugs or agents act on the targeted cells without affecting normal healthy cells. Literature has shown that several nanoparticles, organic and inorganic nanoparticles, have been used as the drug delivery system in different types of oral cancers such as oral squamous cell carcinoma, cancer of the tongue, head, and neck cancers. Drugs like cisplatin, 5-fluorouracil, methotrexate, doxorubicin, etc., when coated with nano-polymers have shown better results compared with conventional drugs in oral cancer. Other nanoparticles such as liposomes, hydrogels, nanodiamonds, carbon rods, etc. have also been used with minimal side effects. This paper aims to review and discuss various nanotechnology systems in the field of oral cancer and to evaluate the efficacy of these systems in treating oral cancer compared with conventional drug delivery methods.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"38 6","pages":"1-48"},"PeriodicalIF":2.7,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39470797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2020034715
Anam Javaid, Duaa Zahra, Ayesha Asim, Nehdia Javaid, Usman Ali Ashfaq
Viral infections such as AIDS, hepatitis, herpes keratitis, and herpes labialis became resistant to drugs and it is difficult to design vaccine. In current era drug-resistant viruses are now treated by nanoparticles (NPs) and this field is known as nanobiotechnology that relates nanoscience with the biological system. NPs due to their antiviral activity are used in the treatment of viral diseases. The advantages of using the NP is its specific target action and increase the efficiency of treatment with minimum side effects. Liposomes, quantum dots, polymeric NPs, solid lipid NPs, silver NPs, gold NPs, and magnetic NPs are used to treat viral infections. NP-based therapeutics have completely replaced the usage of drugs and vaccines for viral diseases treatment. Nano vaccines have been investigated for the delivery of drugs; biomaterials-based NPs are in development to be formulated into nano vaccines. But there are limitations in the manufacturing and stabilization of NPs in the body. This review focuses on the antiviral activity of several NPs, its uptake by different viruses for viral disease treatment, nano vaccines, and the limitation of the NPs as nanotherapeutics.
{"title":"Recent Updates on the Role of Nanoparticles in the Treatment of Viral Diseases.","authors":"Anam Javaid, Duaa Zahra, Ayesha Asim, Nehdia Javaid, Usman Ali Ashfaq","doi":"10.1615/CritRevTherDrugCarrierSyst.2020034715","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2020034715","url":null,"abstract":"<p><p>Viral infections such as AIDS, hepatitis, herpes keratitis, and herpes labialis became resistant to drugs and it is difficult to design vaccine. In current era drug-resistant viruses are now treated by nanoparticles (NPs) and this field is known as nanobiotechnology that relates nanoscience with the biological system. NPs due to their antiviral activity are used in the treatment of viral diseases. The advantages of using the NP is its specific target action and increase the efficiency of treatment with minimum side effects. Liposomes, quantum dots, polymeric NPs, solid lipid NPs, silver NPs, gold NPs, and magnetic NPs are used to treat viral infections. NP-based therapeutics have completely replaced the usage of drugs and vaccines for viral diseases treatment. Nano vaccines have been investigated for the delivery of drugs; biomaterials-based NPs are in development to be formulated into nano vaccines. But there are limitations in the manufacturing and stabilization of NPs in the body. This review focuses on the antiviral activity of several NPs, its uptake by different viruses for viral disease treatment, nano vaccines, and the limitation of the NPs as nanotherapeutics.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"38 2","pages":"75-102"},"PeriodicalIF":2.7,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25411550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2021037662
Duaa Zahra, Anam Javaid, Mudassir Iqbal, Iqra Akbar, Usman Ali Ashfaq
Applications of nanoceria in the biomedical field are quite promising, as previous data has shown potential use of nanoceria as therapeutics via radical scavenging and oxidative stress mitigating properties. But, still, there are contradicting reports regarding nanoceria activity, mode of action, and in vitro toxicity in the cell. There are different nanoceria synthesis methods and Ligands for functionalization and loading of nanoceria into drugs for targeted drug delivery. Redox chemistry of nanoceria exerts their anticancer properties through apoptosis and oxidative stress as it can switch between Ce3+ and Ce4+ and act as free radical scavengers. For breast cancer treatment, cerium oxide nanoparticles (CeONPs) can act as protectant for healthy cells against on-going radiotherapy. Similarly, CeONPs were used to make pancreatic cancer cells more sensitive to radiation damage setting them on the apoptotic pathway. Herein, the study reflects the use of nanoceria as a drug delivery system in chemotherapy due to its efficiency in acidic pH and oxidase activity in the microenvironment. A controlled drug delivery system was adapted using a nano-complexes of AMD-GCCNP-DOX, which were then employed against the retinoblastoma cells from the human eye to target the overexpressing chemokine receptor 4 (CXCR4). In radiotherapy, nanoceria acts as radioprotectants due to their free radical scavenging property and inhibit the proliferation and migration of gastric cancer. This paper summarizes the synthesis methods and application of nanoceria in cancer.
{"title":"Synthesis and Therapeutic Potential of Nanoceria against Cancer: An Update.","authors":"Duaa Zahra, Anam Javaid, Mudassir Iqbal, Iqra Akbar, Usman Ali Ashfaq","doi":"10.1615/CritRevTherDrugCarrierSyst.2021037662","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2021037662","url":null,"abstract":"<p><p>Applications of nanoceria in the biomedical field are quite promising, as previous data has shown potential use of nanoceria as therapeutics via radical scavenging and oxidative stress mitigating properties. But, still, there are contradicting reports regarding nanoceria activity, mode of action, and in vitro toxicity in the cell. There are different nanoceria synthesis methods and Ligands for functionalization and loading of nanoceria into drugs for targeted drug delivery. Redox chemistry of nanoceria exerts their anticancer properties through apoptosis and oxidative stress as it can switch between Ce3+ and Ce4+ and act as free radical scavengers. For breast cancer treatment, cerium oxide nanoparticles (CeONPs) can act as protectant for healthy cells against on-going radiotherapy. Similarly, CeONPs were used to make pancreatic cancer cells more sensitive to radiation damage setting them on the apoptotic pathway. Herein, the study reflects the use of nanoceria as a drug delivery system in chemotherapy due to its efficiency in acidic pH and oxidase activity in the microenvironment. A controlled drug delivery system was adapted using a nano-complexes of AMD-GCCNP-DOX, which were then employed against the retinoblastoma cells from the human eye to target the overexpressing chemokine receptor 4 (CXCR4). In radiotherapy, nanoceria acts as radioprotectants due to their free radical scavenging property and inhibit the proliferation and migration of gastric cancer. This paper summarizes the synthesis methods and application of nanoceria in cancer.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"38 5","pages":"1-26"},"PeriodicalIF":2.7,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39298205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2021037145
Anamaria Mendonça Santos, Carina Carvalho Dos Santos, Tiago Bittencourt de Oliveira, Mairim Russo Serafini, Izabel Almeida Alves
In recent years, allergies are on the rise. The growth of allergies cases has changed the immune system's response to new pathogens. The therapy used to treat these diseases is based on allergen avoidance, pharmacotherapy and allergen-specific immunotherapy. The last one has received a lot of interest in the research field, due to the possibility of leading the patient to a cure. In this sense, new allergen immunotherapy need to be developed or improved to increase safety and efficiency. This review aims to evaluate patents published, from 2015 to July 2020, that have developed allergic immunotherapy treatment and administration routes, as well as new alternatives of vehicles, carriers and delivery systems in this context. The advance of new patents has been mostly seen in China and United States. The oral route is the most used in the development of new allergy treatments. However, due to the challenges that still exist in allergy therapy, association with other pathways is interesting to amplify the possibilities and alternatives of treatment. Thus, other routes of administration for allergen-specific immunotherapy such as topical, sublingual and intranasal have been explored in the research and industrial fields. Nevertheless, it has been observed that few studies are using these alternative administration routes, probably due to the higher cost and lack of investments. The delivery systems are also other tools that can be more explored in the allergen immunotherapy formulations. The effectiveness, safety and acceptance of this therapy depends on the development of new formulations and routes of administration.
{"title":"What's New in Allergen Immunotherapy Patents? A Review.","authors":"Anamaria Mendonça Santos, Carina Carvalho Dos Santos, Tiago Bittencourt de Oliveira, Mairim Russo Serafini, Izabel Almeida Alves","doi":"10.1615/CritRevTherDrugCarrierSyst.2021037145","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2021037145","url":null,"abstract":"<p><p>In recent years, allergies are on the rise. The growth of allergies cases has changed the immune system's response to new pathogens. The therapy used to treat these diseases is based on allergen avoidance, pharmacotherapy and allergen-specific immunotherapy. The last one has received a lot of interest in the research field, due to the possibility of leading the patient to a cure. In this sense, new allergen immunotherapy need to be developed or improved to increase safety and efficiency. This review aims to evaluate patents published, from 2015 to July 2020, that have developed allergic immunotherapy treatment and administration routes, as well as new alternatives of vehicles, carriers and delivery systems in this context. The advance of new patents has been mostly seen in China and United States. The oral route is the most used in the development of new allergy treatments. However, due to the challenges that still exist in allergy therapy, association with other pathways is interesting to amplify the possibilities and alternatives of treatment. Thus, other routes of administration for allergen-specific immunotherapy such as topical, sublingual and intranasal have been explored in the research and industrial fields. Nevertheless, it has been observed that few studies are using these alternative administration routes, probably due to the higher cost and lack of investments. The delivery systems are also other tools that can be more explored in the allergen immunotherapy formulations. The effectiveness, safety and acceptance of this therapy depends on the development of new formulations and routes of administration.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"38 6","pages":"105-125"},"PeriodicalIF":2.7,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39470799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2021035767
Munira M Momin, Shaikh Darakhshan Afreen
Several ocular drug delivery (ODD) systems, like hydrogels, microparticles, nano-emulsions, micro-emulsions, and liposomes have been researched, which can govern the drug release and sustain therapeutic levels for a delayed period in the eye. While new drugs targeting methods to the eye are possible by various nanoparticles. Presently in the market, there are fewer choices and need for novel nano-ocular delivery systems as well as therapies for prolonged delivery to the anterior and posterior eye segments. The primary objective of this article is to summarize current discoveries and proven activities of different nano- and microsystems in ODD. This article also depicts some regulatory updates along with the patents granted to the inventor for their work on ODD. Overall, a thought of how the different forthcoming of nanotechnologies like nanoparticles and nanomedicine can be used to investigate the frontiers of ODD and treatment can be withdrawn by this article.
{"title":"Nanoformulations and Highlights of Clinical Studies for Ocular Drug Delivery Systems: An Overview.","authors":"Munira M Momin, Shaikh Darakhshan Afreen","doi":"10.1615/CritRevTherDrugCarrierSyst.2021035767","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2021035767","url":null,"abstract":"<p><p>Several ocular drug delivery (ODD) systems, like hydrogels, microparticles, nano-emulsions, micro-emulsions, and liposomes have been researched, which can govern the drug release and sustain therapeutic levels for a delayed period in the eye. While new drugs targeting methods to the eye are possible by various nanoparticles. Presently in the market, there are fewer choices and need for novel nano-ocular delivery systems as well as therapies for prolonged delivery to the anterior and posterior eye segments. The primary objective of this article is to summarize current discoveries and proven activities of different nano- and microsystems in ODD. This article also depicts some regulatory updates along with the patents granted to the inventor for their work on ODD. Overall, a thought of how the different forthcoming of nanotechnologies like nanoparticles and nanomedicine can be used to investigate the frontiers of ODD and treatment can be withdrawn by this article.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"38 4","pages":"79-107"},"PeriodicalIF":2.7,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39292962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2020034975
Earle Radha Rani, G V Radha
Self-emulsifying drug delivery system (SEDDS), a category of lipid-based technology, has gained interest in the recent years for enhancement of solubility and bioavailability of poorly water-soluble drugs. With the progress of research in this field, novel excipients have been developed with enhanced properties. But excipient selection is the key hurdle in the formulation of SEDDS. The objective of this review is to summarize different types of oils, surfactants, co-surfactants which are the key components of liquid SEDDS (L-SEDDS), various carriers utilized in the conversion of L-SEDDS to solid SEDDS (S-SEDDS), their description, properties, grades, and applications in pharmacy. This article provides an overview of solidification techniques to transform L-SEDDS to S-SEDDS which are more stable and have better patience compliance. This review presents numerous literature reports on various excipients used and the discussion on how these excipients affect the final results.
{"title":"Insights into Novel Excipients of Self-Emulsifying Drug Delivery Systems and Their Significance: An Updated Review.","authors":"Earle Radha Rani, G V Radha","doi":"10.1615/CritRevTherDrugCarrierSyst.2020034975","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2020034975","url":null,"abstract":"<p><p>Self-emulsifying drug delivery system (SEDDS), a category of lipid-based technology, has gained interest in the recent years for enhancement of solubility and bioavailability of poorly water-soluble drugs. With the progress of research in this field, novel excipients have been developed with enhanced properties. But excipient selection is the key hurdle in the formulation of SEDDS. The objective of this review is to summarize different types of oils, surfactants, co-surfactants which are the key components of liquid SEDDS (L-SEDDS), various carriers utilized in the conversion of L-SEDDS to solid SEDDS (S-SEDDS), their description, properties, grades, and applications in pharmacy. This article provides an overview of solidification techniques to transform L-SEDDS to S-SEDDS which are more stable and have better patience compliance. This review presents numerous literature reports on various excipients used and the discussion on how these excipients affect the final results.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"38 2","pages":"27-74"},"PeriodicalIF":2.7,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25411548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2021035845
Awesh Yadav, Rahul Shukla, S J S Flora
Nanodiamonds (ND) belong to the nano-carbon family, which involves several synthesis, post-synthesis methods, and other modifications for ND preparation. NDs have played vital role both inside and outside of medicine in recent years. The study of NDs has stated in early 1960s, NDs are smaller particles with a size of about 4-5 nm with confined size distribution, large-scale synthesis at lower costs relying on the carbon explosives ignition, apparent surface functional design along with bio-conjugation and extreme biocompatibility. It has been predicted that the ND's magnetic characteristics will contribute to the up-growth of various therapeutic promoters for delivery vehicles, diagnostic probes, gene therapy, tissue scaffolds, anti-bacterial and anti-viral treatments, and devices like nano-robots. Furthermore, the wide applications of biotechnology have displayed the potential usage of NDs in certain bioanalytical needs like fluorescent bio labeling through fluorescent and protein purification of proteins. In this current review, the determination of ND's design, property, classes, constancy, organization, surface modification, biocompatibility, and its applications in the biomedical field have penned. The usage of ND as anti-neoplastic agents and in other health related formulations have displayed exceptional results for future growth. Additionally, NDs provide other functionalities such as production of biodegradable surgical devices of bone, the assassination of drug resistant microbes and viruses, tissue engineering scaffolds, and aids in the delivery of genetic matter into the nucleus of cells.
{"title":"Nanodiamonds: A Versatile Drug-Delivery System in the Recent Therapeutics Scenario.","authors":"Awesh Yadav, Rahul Shukla, S J S Flora","doi":"10.1615/CritRevTherDrugCarrierSyst.2021035845","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2021035845","url":null,"abstract":"<p><p>Nanodiamonds (ND) belong to the nano-carbon family, which involves several synthesis, post-synthesis methods, and other modifications for ND preparation. NDs have played vital role both inside and outside of medicine in recent years. The study of NDs has stated in early 1960s, NDs are smaller particles with a size of about 4-5 nm with confined size distribution, large-scale synthesis at lower costs relying on the carbon explosives ignition, apparent surface functional design along with bio-conjugation and extreme biocompatibility. It has been predicted that the ND's magnetic characteristics will contribute to the up-growth of various therapeutic promoters for delivery vehicles, diagnostic probes, gene therapy, tissue scaffolds, anti-bacterial and anti-viral treatments, and devices like nano-robots. Furthermore, the wide applications of biotechnology have displayed the potential usage of NDs in certain bioanalytical needs like fluorescent bio labeling through fluorescent and protein purification of proteins. In this current review, the determination of ND's design, property, classes, constancy, organization, surface modification, biocompatibility, and its applications in the biomedical field have penned. The usage of ND as anti-neoplastic agents and in other health related formulations have displayed exceptional results for future growth. Additionally, NDs provide other functionalities such as production of biodegradable surgical devices of bone, the assassination of drug resistant microbes and viruses, tissue engineering scaffolds, and aids in the delivery of genetic matter into the nucleus of cells.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"38 4","pages":"39-78"},"PeriodicalIF":2.7,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39292961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2021034903
Mallesh Kurakula, Li Chen, Amit K Tiwari, Nuggehally R Srinivas, Ranjeet Prasad Dash, Peter R Panizzi, Robert D Arnold, R Jayachandra Babu
Melanoma is one of the most aggressive forms of cancer with limited treatment options available. Successful treatment involves a combination of surgical resection of the tumor; chemotherapy and immunotherapy. Given their complex nature, the rapid development of drug resistance and metastatic spread, nanotechnology-based therapeutics are an attractive option for effective melanoma treatment. Nano-vesicular-based delivery systems hold the promise of aiding in the diagnosis and treatment of melanoma. These formulations can improve targeted delivery, deliver insoluble drugs belonging to class II, biopharmaceutical classification system, and alter drug pharmacokinetics and exposure profiles. These nanometer-sized carriers predominantly bypass the reticuloendothelial system and, thereby, improve blood circulation time and enhance tumor cell uptake with reduced toxicity. In this review, various lipid-based nano-formulations used in the diagnosis, treatment, or both for melanoma are discussed. Utilization of these na-no-formulations with a single drug or a combination of drugs, nucleic acid-based compounds (small interfering RNA, DNA) and targeting antibodies as other possibilities for melanoma are reviewed. We also present a state-of-the-art overview of alternative therapeutic approaches for the treatment of melanoma, such as photodynamic, immune, and gene therapies.
{"title":"Recent Advances in Lipid-Based Nanovesicular Delivery Systems for Melanoma Therapy.","authors":"Mallesh Kurakula, Li Chen, Amit K Tiwari, Nuggehally R Srinivas, Ranjeet Prasad Dash, Peter R Panizzi, Robert D Arnold, R Jayachandra Babu","doi":"10.1615/CritRevTherDrugCarrierSyst.2021034903","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2021034903","url":null,"abstract":"<p><p>Melanoma is one of the most aggressive forms of cancer with limited treatment options available. Successful treatment involves a combination of surgical resection of the tumor; chemotherapy and immunotherapy. Given their complex nature, the rapid development of drug resistance and metastatic spread, nanotechnology-based therapeutics are an attractive option for effective melanoma treatment. Nano-vesicular-based delivery systems hold the promise of aiding in the diagnosis and treatment of melanoma. These formulations can improve targeted delivery, deliver insoluble drugs belonging to class II, biopharmaceutical classification system, and alter drug pharmacokinetics and exposure profiles. These nanometer-sized carriers predominantly bypass the reticuloendothelial system and, thereby, improve blood circulation time and enhance tumor cell uptake with reduced toxicity. In this review, various lipid-based nano-formulations used in the diagnosis, treatment, or both for melanoma are discussed. Utilization of these na-no-formulations with a single drug or a combination of drugs, nucleic acid-based compounds (small interfering RNA, DNA) and targeting antibodies as other possibilities for melanoma are reviewed. We also present a state-of-the-art overview of alternative therapeutic approaches for the treatment of melanoma, such as photodynamic, immune, and gene therapies.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"38 4","pages":"1-38"},"PeriodicalIF":2.7,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39293515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2021035650
Sunita Dahiya, Rajiv Dahiya, Eliud Hernández
Nanocarriers are nanostructured vehicles employed to deliver anticancer drugs to the targeted tumor sites in the body. Nanocarriers have been successfully employed to circumvent certain limitations of conventional anticancer drug delivery while providing greater bioavailability, prolonged circulation time and higher tumor accumulation for enhanced therapeutic outcomes in cancer treatment. Nanocarriers are also responsive to functionalization to tailor their pharmaco-kinetics and achieve enhanced therapeutic outcomes in cancer therapy. Among organic, inorganic and hybrid type, several nanocarriers have gained approval for use in cancer patients, while many more are under clinical development. For the last two decades, cancer immunotherapy-based advanced targeting approaches such as monoclonal antibodies, antibody drug conjugates and immune checkpoint inhibitors that utilize human immune system functions have vastly developed which furnish better treatment options in several intractable cancers compared with traditional cancer therapies. This review discusses the imperative role of tumor vasculature in passive and active targeting of anticancer drugs using organic and inorganic nanocarriers and the current research efforts underway. The advanced targeting approaches for treatment of various cancers and their most recent clinical development scenario have been comprehensively explored. Further, potential challenges associated with each type of nanocarrier, and their translational obstacles are addressed.
{"title":"Nanocarriers for Anticancer Drug Targeting: Recent Trends and Challenges.","authors":"Sunita Dahiya, Rajiv Dahiya, Eliud Hernández","doi":"10.1615/CritRevTherDrugCarrierSyst.2021035650","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2021035650","url":null,"abstract":"<p><p>Nanocarriers are nanostructured vehicles employed to deliver anticancer drugs to the targeted tumor sites in the body. Nanocarriers have been successfully employed to circumvent certain limitations of conventional anticancer drug delivery while providing greater bioavailability, prolonged circulation time and higher tumor accumulation for enhanced therapeutic outcomes in cancer treatment. Nanocarriers are also responsive to functionalization to tailor their pharmaco-kinetics and achieve enhanced therapeutic outcomes in cancer therapy. Among organic, inorganic and hybrid type, several nanocarriers have gained approval for use in cancer patients, while many more are under clinical development. For the last two decades, cancer immunotherapy-based advanced targeting approaches such as monoclonal antibodies, antibody drug conjugates and immune checkpoint inhibitors that utilize human immune system functions have vastly developed which furnish better treatment options in several intractable cancers compared with traditional cancer therapies. This review discusses the imperative role of tumor vasculature in passive and active targeting of anticancer drugs using organic and inorganic nanocarriers and the current research efforts underway. The advanced targeting approaches for treatment of various cancers and their most recent clinical development scenario have been comprehensively explored. Further, potential challenges associated with each type of nanocarrier, and their translational obstacles are addressed.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"38 6","pages":"49-103"},"PeriodicalIF":2.7,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39470798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.1615/CritRevTherDrugCarrierSyst.2021035222
Shallu Kutlehria, Mandip Singh Sachdeva
There is emergent need for in vitro models which are physiologically correct, easy to reproduce, and mimic characteristic functionalities of desired tissue, organ, or diseases state for ophthalmic drug screening, as well as disease modeling. To date, a variety of in vitro models have been developed for the applications ranging from 2D cell culture-based monolayers, multilayer, or co-culture models, to 3-dimensional (3D) organoids, 3D printed and organ on chip systems. Each model has its own pros and cons. While simple models are easier to create, and faster to reproduce, they lack recapitulation of the complex framework, functionalities, and properties of tissues or their subunits. Recent advancements in technologies and integration with tissue engineering and involvement of microfluidic systems have offered novel platforms which can better mimic the in vivo microenvironment, thus possessing potential in transformation of ophthalmic drug development. In this review we summarize existing in vitro ocular models while discussing applicability, drawbacks associated with them, and possible future applications.
{"title":"Role of In Vitro Models for Development of Ophthalmic Delivery Systems.","authors":"Shallu Kutlehria, Mandip Singh Sachdeva","doi":"10.1615/CritRevTherDrugCarrierSyst.2021035222","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2021035222","url":null,"abstract":"<p><p>There is emergent need for in vitro models which are physiologically correct, easy to reproduce, and mimic characteristic functionalities of desired tissue, organ, or diseases state for ophthalmic drug screening, as well as disease modeling. To date, a variety of in vitro models have been developed for the applications ranging from 2D cell culture-based monolayers, multilayer, or co-culture models, to 3-dimensional (3D) organoids, 3D printed and organ on chip systems. Each model has its own pros and cons. While simple models are easier to create, and faster to reproduce, they lack recapitulation of the complex framework, functionalities, and properties of tissues or their subunits. Recent advancements in technologies and integration with tissue engineering and involvement of microfluidic systems have offered novel platforms which can better mimic the in vivo microenvironment, thus possessing potential in transformation of ophthalmic drug development. In this review we summarize existing in vitro ocular models while discussing applicability, drawbacks associated with them, and possible future applications.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"38 3","pages":"1-31"},"PeriodicalIF":2.7,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694856/pdf/nihms-1762824.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39283798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}